PolTREG Spolka Akcyjna · GPW:PTG

PolTREG Spolka Akcyjna — PolTREG — Investor Presentation (December 2023)

28 slides from PolTREG Spolka Akcyjna's investor presentation, Dec 19, 2023

  1. Slide 1: The promises of TREG autoimmune therapy, all in one hand

    Slide 1: The promises of TREG autoimmune therapy, all in one hand

    The promises of TREG autoimmune therapy, all in one hand Innovative therapies December 2023 for autoimmune diseases

  2. Slide 2: Forward-looking statements

    Slide 2: Forward-looking statements

    Forward-looking statements The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "e

  3. Slide 3: The promises of TREG autoimmune therapy, all in one hand

    Slide 3: The promises of TREG autoimmune therapy, all in one hand

    The promises of TREG autoimmune therapy, all in one hand • Three clinical assets that will deliver value + milestones • PTG007 = a potential disease-modifying treatment for T1D, Multiple Sclerosis (MS) • PTG-007 – ready for Phase 2/3 trial in • PolTREG is a one-stop shop Type-1 Diabetes (T1D), pendi

  4. Slide 4: Largest, most advanced pipeline of cell therapies for autoimmune disease

    Slide 4: Largest, most advanced pipeline of cell therapies for autoimmune disease

    Largest, most advanced pipeline of cell therapies for autoimmune disease Therapeutic area Indication Discovery Preclinical Phase I Phase II Phase III Type 1 diabetes Early onset (stage 3) PTG-007+ / rituximab Presymptomatic (stage 1/2) PTG-007+ / rituximab Multiple sclerosis Relapsing-remitting (RRM

  5. Slide 5: Based in Poland, with a global outlook

    Slide 5: Based in Poland, with a global outlook

    Based in Poland, with a global outlook Shares (%) 21,31 % PAAN CAPITAL 30,22 % Venture Fundusz Inwestycyjny Zamknięty Marek-Trzonkowska Natalia Trzonkowski Piotr TFI Allianz 3,54 % 18,97 % POLAND PTE Allianz Botaniczna 20 80-298 Gdańsk 7,63 % Myśliwiec Małgorzata 5,24 % 7,85 % Pozostali 50 employees

  6. Slide 6: PolTREG (Ticker PTG.WSE) – Market cap USD 67m

    Slide 6: PolTREG (Ticker PTG.WSE) – Market cap USD 67m

    PolTREG (Ticker PTG.WSE) – Market cap USD 67m Free float 65% PolTREG Share price / Volume 1yr Share Statistics • IPO in 2021 on Warsaw Stock Exchange • Maket cap PLN 273m (USD 67m) • Shares outstanding 4,66m • Free Float 65% • Held by insiders 35,33% • Held by institutions 38,22% • Current share pri

  7. Slide 7: Experienced leaders, front-line scientists

    Slide 7: Experienced leaders, front-line scientists

    Experienced leaders, front-line scientists Prof. Piotr Trzonkowski Mariusz Jabłoński Paulina Kocenko-Merks Grzegorz Orlik CEO, Founder & Board Director CBO, Board Director CFO, Board Director Head Medical Affairs • Professor of medical science, • 20+ years of experience in • 15+ years of professiona

  8. Slide 8: Experienced leaders, front-line scientists

    Slide 8: Experienced leaders, front-line scientists

    Experienced leaders, front-line scientists Camilo Ricordi, Artur Tadeusz Bossowski, Agata Przemysława Chrobot, Kamil Chwojnicki Przemysława Jarosz-Chobot Iwona Kurkowska-Jastrzębska MD, Professor of Medicine MD, PhD, Professor of Medicine MD, PhD, Professor of Medicine MD, PhD MD, PhD, Professor of

  9. Slide 9: Treg cells are a potential therapy for a range of auto-immune diseases

    Slide 9: Treg cells are a potential therapy for a range of auto-immune diseases

    Treg cells are a potential therapy for a range of auto-immune diseases Brain Multiple sclerosis Pancreatic islets Type 1 diabetes Joints Rheumatoid arthritis Gut Inflammatory Bowel Disease 9 poltreg.com

  10. Slide 10: PTG007 has shown the capacity to slow progression of T1D

    Slide 10: PTG007 has shown the capacity to slow progression of T1D

    PTG007 has shown the capacity to slow progression of T1D A potential disease-modifying candidate therapy for early onset T1D PTG007 has MAST CELL ….through a range of cellular a potential to reduce mechanisms insulin dependance... NK VII DC I Suppression of antigen presentation VI OX40L OX40 I Inhib

  11. Slide 11: Using the immune system's own police force

    Slide 11: Using the immune system's own police force

    Using the immune system’s own police force Other drugs TREGs Other drugs TREGs TREGs keep the immune system in check and prevent other immune cells from attacking the body’s own tissues. TREGs operate at the site TREGs switch off when the of inflammation only inflammation is over 11 poltreg.com

  12. Slide 12: Key milestones for value creation 2024-2025

    Slide 12: Key milestones for value creation 2024-2025

    Key milestones for value creation 2024-2025 Candidate H1 24 H2 24 2025 Event Approvals to use new research and production facilities Regulatory approval facility Poland in Poland for further clinical studies PTG-007+ (T1D early onset) End of post-trial long-term safety/efficacy study (10-year follow

  13. Slide 13: TREG therapy is a growth market

    Slide 13: TREG therapy is a growth market

    TREG therapy is a growth market Recent transactions: Development of therapy for inflammatory bowel disease IBD & $13.64 • 1,9 mld USD - biodollar 14 12 10 7,6% CAGR Development of TREG therapy • 75 mln USD – upfront payment & 8 $7.59 $13.64 billion $1.9 billion billion • 45 mln USD – milestone 6 4 D

  14. Slide 14: Type-1 Diabetes: combination therapy in PTG007+ trial shows better remission

    Slide 14: Type-1 Diabetes: combination therapy in PTG007+ trial shows better remission

    Type-1 Diabetes: combination therapy in PTG007+ trial shows better remission December 2021 data „ Any delay in the administration of insulin is significant, because it means that you „ have been successful in targeting the cause of the disease, and you need to take advantage of that. IQVIA report 14

  15. Slide 15: T1D: Superior results from combined therapy over any monotherapy

    Slide 15: T1D: Superior results from combined therapy over any monotherapy

    T1D: Superior results from combined therapy over any monotherapy First loss of remission - censored Total Daily Dose of Insulin per kg b.w. TREGs + anti-CD20 TREGs + anti-CD20 1, 0 TREGs TREGs 1,00 Control Control TDD/kg b. w. (UI/kg b. w.) 0,8 Remission probability 0,75 0,6 Remission border 0,50 0,

  16. Slide 16: What's next for early onset T1D?

    Slide 16: What's next for early onset T1D?

    What’s next for early onset T1D? Phase 2/3 study ready Potentially pivotal study for 250 patients (5 x 50) Option to stop Phase 2 trial and Duration to launch, requires market authorization start Phase 3 if one of the partner funding interventional arms shows 5 arms superior results 18months 16 polt

  17. Slide 17: Presymptomatic T1D: phase 2 study

    Slide 17: Presymptomatic T1D: phase 2 study

    Presymptomatic T1D: phase 2 study Pediatric patients with 150 patients Protocol signed, contracting Up to Planned start presymptomatic T1D of sites awaiting approval 4 arms 5 years 3Q2024 pending EMA approval 17 poltreg.com

  18. Slide 18: A therapeutic candidate for each stage of T1D

    Slide 18: A therapeutic candidate for each stage of T1D

    A therapeutic candidate for each stage of T1D Triggering Genetic Active Loss of insulin Overt IDDM susceptibility autoimmunity secretion diabetes PTG-007 – polyclonal PTG-007 – polyclonal Tregs TregVAC1.0 & 2.0 trials • presymptomatic • early onset • few autoantigens • many autoantigens • HIGH volum

  19. Slide 19: Can TREGS also be a game changer in MS?

    Slide 19: Can TREGS also be a game changer in MS?

    Can TREGS also be a game changer in MS? >2.8 million There are no curative therapies Multiple Sclerosis affects more than 2.8 TREGs have the potential to ameliorate MS million people worldwide as part of a combination therapy Promising early PolTREG $33.98 billion results show remission Market expec

  20. Slide 20: MS: Promising early signs of efficacy

    Slide 20: MS: Promising early signs of efficacy

    MS: Promising early signs of efficacy Number of lesions Intravenous Intrathecal 14patients 3 years Phase 1/2 RRMS study Study dates with 14 patients 2015-2018 150 Index of changes 100 Almost no increase in volume of Intrathecal administration existing lesions, almost no new showed positive efficacy

  21. Slide 21: What's next? New phase 1/2 study in MS

    Slide 21: What's next? New phase 1/2 study in MS

    What’s next? New phase 1/2 study in MS One study each in primary Each trial expected Expected start date: 2H 2024 A combined 105 patients: progressive MS (PPMS) and to have three arms for both trials relapsing-remitting MS (RRMS) 3 arms 2024 60 for PPMS 45 for RRMS 21 poltreg.com

  22. Slide 22: Next generation Engineered TREGS

    Slide 22: Next generation Engineered TREGS

    Next generation „ Engineered TREGS We […] view CART cell therapy […] in refractory autoimmune disease as the most disruptive and high commercial potential opportunity since immune-oncology re-emerged in 2011 Andrew Baum, Citi research note, August 2023 22 poltreg.com

  23. Slide 23: CARTREGs as a platform for neurodegenerative disease

    Slide 23: CARTREGs as a platform for neurodegenerative disease

    CARTREGs as a platform for neurodegenerative disease The CAR receptor directs TREG cells This can help the degradation CARTREGS are a platform to glia cells, which protect the nervous of neural cells in a range therapy for neurodegenerative system of autoimmune diseases disease 23 poltreg.com

  24. Slide 24: The first in-patient CARTREG trial in neurodegenerative disease?

    Slide 24: The first in-patient CARTREG trial in neurodegenerative disease?

    The first in-patient CARTREG trial in neurodegenerative disease? Phase I clinical trial can Two separate clinical Partnership PolTREG’s long experience Expect trial start as soon as CMC trials planned: with AZ Therapies with TREGs will make it easier launch late approval, animal studies to obtain ap

  25. Slide 25: Security in one of Europe's largest development centres

    Slide 25: Security in one of Europe's largest development centres

    Security in one of Europe’s largest development centres PolTREG achieved nearly 100% purity in TREGS expanded ex vivo, and was the first ever to inject patients with autologous cells. 25 poltreg.com

  26. Slide 26: Building a state-of-the art manufacturing plant

    Slide 26: Building a state-of-the art manufacturing plant

    Building a state-of-the art manufacturing plant 2021 2023 PolTREG started building one of the most The new facility is now ready and Production facility for third parties for advanced in Europe for cell and gene therapy expected to receive regulatory wide range of polyclonal and manufacturing in 202

  27. Slide 27: Building a state-of-the art manufacturing plant

    Slide 27: Building a state-of-the art manufacturing plant

    Building a state-of-the art manufacturing plant Pharma companies Clinical centres • Expand BD and Alliance • For early access therapies for Management Strategy patients with early-onset T1D • Business partnerships Pharma companies Academic partners • For R&D • Up-and-running CDMO, GMP certified • Fo

  28. Slide 28: Contact us

    Slide 28: Contact us

    Contact us office@poltreg.com Botaniczna 20 Street, Mariusz Jablonski Gdansk, Poland Chief Business Officer m.jablonski@poltreg.com Chris Maggos, Cohesion Bureau, Investor Relations chris.maggos@cohesionbureau.com Innovative therapies poltreg.com for autoimmune diseases

Source: Internet Archive copy of poltreg.com

More decks from PolTREG Spolka Akcyjna

All 15 PolTREG Spolka Akcyjna decks